# US 2026/0256816 A1 · Pharmaceutical composition for preventing or treating brain tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256816 A1
- Document ID: US20260256816A1
- Status: Published application
- Kind: A1
- Application number: 19/491,255
- Filed: 2024-06-07
- Published: 2026-09-03
- Earliest claimed: 2023-06-09
- Assignees: Astrion Inc.
- Applicants: Astrion Inc.
- Inventors: Geuk-Rae JEONG; Hee Jo PARK
- Web page: https://patentgrep.com/patent/US20260256816A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/381: having five-membered rings
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07D 209/46: with an oxygen atom in position 1
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07F 9/5333: {Arylalkane phosphine oxides or thioxides (C07F9/5329 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided is a method for treating a brain tumor by administering a pharmaceutically effective amount of a compound of Chemical Formulae 1 to 6 or a combination thereof, or a pharmaceutically acceptable salt thereof, or a composition comprising the same as an active, alone or with a targeted anticancer agent against EGFR, wherein the compound simultaneously inhibits ANO1 and EGFR in brain tumor cells, thereby exhibiting a strong anticancer effect through dual inhibition of the two proteins, further enhancing the efficacy of an anticancer agent when used in combination with an EGFR targeted anticancer agent, and inhibiting cancer resistance; and therefore the compound itself can be used as a dual target anticancer agent of ANO1 and EGFR, and can also be used as a combination agent of EGFR targeted therapy, being expected to be variously utilized in the field of prevention and treatment of brain tumors.

## Claims

### Claim at position 1

-25. (canceled)

### Claim 26

A method for treating a brain tumor, comprising administering to a subject in need thereof, a pharmaceutically effective amount of at least one compound selected from the group consisting of the compounds represented by Chemical Formulae 1 to 6 or a pharmaceutically acceptable salt thereof, or a composition comprising the same, as an active ingredient.

### Claim 27 (depends on 26)

The method of claim 26, wherein the brain tumor is associated with at least one mutation selected from the group consisting of EGFR (epidermal growth factor receptor) and ANO1 (Anoctamin 1).

### Claim 28 (depends on 26)

The method of claim 26, wherein the compound or pharmaceutically acceptable salt thereof simultaneously inhibits EGFR and ANO1.

### Claim 29 (depends on 26)

The method of claim 26, wherein the compound or pharmaceutically acceptable salt thereof satisfies at least one property selected from the group consisting of:
(a) inhibiting tumor metastasis; and
(b) suppressing resistance of cancer to an anticancer agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein the anticancer agent is a targeted anticancer agent against a tyrosine kinase.

### Claim 31 (depends on 30)

The method of claim 30, wherein the tyrosine kinase is one or more selected from the group consisting of EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1 (ROS Proto-Oncogene 1), BRAF (B-Raf Proto-Oncogene), HER2 (human epidermal growth factor receptor 2), RET (Ret Proto-Oncogene), NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), MET (Mesenchymal-Epithelial Transition factor), and NRG1 (Neuregulin 1).

### Claim 32 (depends on 26)

The method of claim 26, wherein the compound, the pharmaceutically acceptable salt thereof, or the composition comprising the same as an active ingredient is administered in combination with a targeted anticancer agent against a tyrosine kinase.

### Claim 33 (depends on 32)

The method of claim 32, wherein the compound, the pharmaceutically acceptable salt thereof, or the composition comprising the same as an active ingredient is administered simultaneously, separately, or sequentially with the targeted anticancer agent.

### Claim 34

A method for treating a brain tumor, comprising administering to a subject in need thereof, a pharmaceutically effective amount of:
(i) at least one compound selected from the group consisting of the compounds represented by Chemical Formulae 1 to 6 or a pharmaceutically acceptable salt thereof, and
(ii) a targeted anticancer agent against EGFR:

### Claim 35 (depends on 34)

The method of claim 34, wherein the compound or pharmaceutically acceptable salt thereof inhibits resistance of brain tumor cells to the targeted anticancer agent against EGFR.

### Claim 36 (depends on 34)

The method of claim 34 wherein the compound or pharmaceutically acceptable salt thereof and the targeted anticancer agent against EGFR are mixed together in the form of a mixed formulation.

### Claim 37 (depends on 34)

The method of claim 34, wherein the compound or pharmaceutically acceptable salt thereof and the targeted anticancer agent against EGFR are separately formulated and are administered simultaneously, separately, or sequentially.

### Claim 38

A method of enhancing anticancer effect of a brain tumor anticancer agent, comprising administering to a subject in need thereof, a brain tumor anticancer agent and a pharmaceutically effective amount of at least one compound selected from the group consisting of the compounds represented by Chemical Formulae 1 to 6 or a pharmaceutically acceptable salt thereof, or a composition comprising the same, as an active ingredient:

### Claim 39 (depends on 38)

The method of claim 38, wherein the brain tumor anticancer agent is a targeted anticancer agent against a tyrosine kinase.

### Claim 40 (depends on 39)

The method of claim 39, wherein the tyrosine kinase is one or more selected from the group consisting of EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), ROS1 (ROS Proto-Oncogene 1), BRAF (B-Raf Proto-Oncogene), HER2 (human epidermal growth factor receptor 2), RET (Ret Proto-Oncogene), NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1), MET (Mesenchymal-Epithelial Transition factor), and NRG1 (Neuregulin 1).

### Claim 41 (depends on 38)

The method of claim 38, wherein the composition is administered simultaneously, separately, or sequentially with the brain tumor anticancer agent.
